COMMITTED TO DISCOVERING BEST-IN-CLASS THERAPIES
TO CONQUER INFLAMMATORY and immunologic DISEASES

Ms. Lyons-Williams joined our board in 2021 as an independent director with more than 20 years of industry experience spanning pharmaceutical and emerging biotech companies. Currently, she serves as President and CEO of Abdera Therapeutics, a privately held biopharmaceutical company developing precision radiopharmaceuticals for cancer.

Prior to Abdera, she was President and Chief Operating Officer at Neumora Therapeutics. Previously, Ms. Lyons served as Chief Commercial officer at Dermira (NASDAQ: DERM) until its acquisition by Eli Lilly in 2020. Prior to Dermira, Ms. Lyons was Vice President, Sales and Marketing at Allergan (NYSE:AGN) Ms. Lyons-Williams currently serves as an independent director on the board of Contineum Therapeutics and previously served as an independent director for Pipeline Therapeutics and Five Prime Therapeutics (NASDAQ:FPRX) until its acquisition by Allergan in 2021.

Ms. Lyons-Williams earned her B.A. from Virginia Tech and her M.B.A. from Carlson School of Management at the University of Minnesota.

Dr. Braunstein joined our board in June 2025. He brings over 30 years of knowledge and experience from diverse biotechnology and pharmaceutical industry vantage points. He has been an operating partner at Aisling Capital since 2015. Until March 2025, Dr. Braunstein served as President and Chief Executive Officer as well as board member of Marinus Pharmaceuticals, Inc., a neurology therapeutics company acquired by Immedica Pharma AB. Prior to that, he served as Senior Vice President, Strategy and Chief Operating Officer at Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company. Prior to Pacira, Dr. Braunstein spent 12 years with J.P. Morgan Asset Management as a Healthcare Analyst and Managing Director and as Portfolio Manager of the JP Morgan Global Healthcare Fund. He currently serves on the board of directors for atai Life Sciences N.V., a clinical-stage biopharmaceutical company, Caribou Biosciences, Inc., a clinical-stage CRISPR genome-editing biopharmaceutical company, and Site One Therapeutics, a clinical-stage neurology company that is being acquired by Eli Lilly. Dr. Braunstein previously served on the board of directors of Trevena Inc., Esperion Therapeutics, Inc., Ziopharm Oncology Inc., Protara Therapeutics, Inc. (previously known as ArTara Therapeutics, Inc.) and Constellation Pharmaceuticals, Inc.

Dr. Braunstein began his career as a practicing physician at the Summit Medical Group and as an Assistant Clinical Professor at Albert Einstein College of Medicine and Columbia University Medical Center. Dr. Braunstein received an M.D. from the Albert Einstein College of Medicine and a BASc in biology from Cornell University.

Dr. Dombkowski has joined our board in June 2025. She brings more than 20 years of experience as an operating executive, entrepreneur and investor. She is currently CEO and President of Cellics Therapeutics, a biotechnology company developing novel biologics to address significant unmet medical needs in inflammation and immunology. Prior to Cellics, she served as CEO and Co-founder of Alladapt Immunotherapeutics, a biopharmaceutical company that developed prescription therapies to treat food allergy; she was CEO and Co-founder of SpoonfulOne, a company focused on early allergen introduction; and was CEO and Co-founder of Before Brands, Inc., a company focused on innovative nutritional products. Dr. Dombkowski also served as Chief Business Officer and Vice President of Operations for 23andMe. She spent 15 years as a Managing Director at venture capital firms MPM Capital and Bay City Capital, and earlier in her career was an Equity Analyst for Tiger Management L.L.C. and for Dresdner RCM Global Investors.

Dr. Dombkowski holds a Ph.D. in mathematics from Rice University and received her B.A. in mathematics from Wellesley College.

Dr. Giordano joined our board in January 2018 as an independent board member, bringing more than 15 years of experience leading pharmaceutical research and development organizations. Most recently, he served as Senior Vice President and Head of Development, Oncology and Immuno-Oncology for Bristol-Myers Squibb, where he was responsible for the development strategy of the enterprise for this therapeutic area, as well as direction for eight teams working on innovative medicines to improve the standard of care for patients, including Opdivo^®, Yervoy^®, Empliciti™, and Sprycel^®. Prior to this role, Dr. Giordano held positions of increasing responsibility within the research and development organization, leading the development of more than a dozen molecules in the United States, the European Union and Asia. Before joining BMS, he served as Assistant Professor of Medicine and Founding Director of the Cornell Clinical Trials Unit, a National Institutes of Health and Industry-supported AIDS clinical trials center at New York Hospital-Cornell University Medical Center. Dr. Giordano has served on the board of directors of Achilles Ltd and Oncovalent, Sumovalent and Arovalent Therapeutics (privately held biopharmaceutical companies) through 2024 and previously served as the Chief Medical Officer and on the board of directors of Epizyme, Inc., a biopharmaceutical company, from March 2018 to August 2022.

He earned his M.D. and completed his residency and fellowship training at The New York Hospital/Weill Cornell Medical and received his B.A. in Natural Sciences cum laude from The Johns Hopkins University.

Dr. Gray joined our board in December 2019. She is President of Gray Strategic Advisors, LLC, a biotechnology strategic planning and advisory firm. Previously, she served as Senior Analyst and Portfolio Manager of Federated Kaufmann Fund where she was responsible for over $1 billion in healthcare investments including in biotechnology, specialty pharmaceutical, pharmaceutical and healthcare services companies. Prior to Federated, she served as a biotechnology equity research analyst at multiple firms. Earlier in her career, she worked as a senior scientist both at Schering Plough Research and NeoRx Corporation. She currently serves on the boards of Compass Therapeutics Inc., Keros Therapeutics, Inc. and BioAtla Inc., and previously served on the board of many public and private biotech companies.

Dr. Gray holds a Bachelor of Science degree from the University of South Carolina, a Ph.D. in pharmacology from the University of Vermont, and completed her post-doctoral work at Northwestern University Medical School and at the Yale University School of Medicine.

Ms. Kozick joined our board in December 2016 as an independent board member. She has more than 25 years of experience in the biopharmaceutical industry, including 15 years of strategic commercial leadership in oncology with a focus in immuno-oncology.

Ms. Kozick retired from Bristol-Myers Squibb (BMS) where she most recently served as Vice President and Head of Immune-Oncology/Oncology Product & Portfolio Strategy, and Opdivo and Yervoy Life Cycle Management. Prior to that, she held several key positions including Vice President, Commercial Lead for Opdivo and Immuno-Oncology Platform Strategy, and was instrumental in establishing BMS’s International Immuno-Oncology Network (II-ON).

Ms. Kozick received her B.S. and M.S. from SUNY Upstate Medical University, and her M.B.A. from Chapman University.

Dr. Wong is a physician/scientist that brings to RAPT Therapeutics over 25 years of experience leading organizations at the forefront of innovative drug development. Prior to RAPT, he served as Senior Vice President, Research at Five Prime Therapeutics which was acquired by Amgen. Prior to Five Prime, Dr. Wong served as Director in the Inflammation Disease Biology Area at Roche. There, he led the discovery and supported the development of Roche’s autoimmune disease portfolio, consisting of more than 20 biologics and small-molecule programs from discovery to late-stage clinical development and through approval.

Dr. Wong received his M.D. from the Weill Cornell Medical College and his Ph.D. in Immunology from Rockefeller University.